Prism Medico (PRISMMEDI) Q2 FY27 Posts Q2 Profit, But Core Business Stalls
The company reported a net profit of ₹0.23 crore for Q2 FY27, yet revenue from operations plunged 64% year-on-year to just ₹0.18 crore, highlighting a pivot in progress.
Prism Medico and Pharmacy's Q2 FY27 results show a net profit of ₹0.23 crore, a turnaround from last year's loss. However, this profit was driven by other income, as core revenue fell sharply, underscoring the company's transitional phase away from its legacy business.
Prism Medico and Pharmacy is navigating a complete business overhaul, shifting from animal feed to pharmaceuticals. The September quarter results capture the awkward middle of that journey: a reported profit built on financial engineering, while the core commercial engine remains nearly idle.
The numbers tell two different stories. Revenue from operations was just ₹0.18 crore, down 64% from the same quarter last year. Yet, the company posted a net profit of ₹0.23 crore, swinging from a loss of ₹0.09 crore in Q2 FY26. This profit was entirely supported by other income, which surged to ₹0.26 crore.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
| Metric | CurrentQ2 FY27 | PreviousQ1 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 0.18YoY -64% | 0.09 | 0.50 |
| Profit (₹ Cr) | 0.23YoY +356% | -0.06 | -0.09 |
The profit engine that isn't
The dramatic 1,429% year-on-year jump in other income, as reported by Flash Finance, is the quarter's real driver. This income is linked to a recent capital raise. The company raised ₹17.5 crore through equity shares and warrants, according to the same outlet, significantly boosting its cash balance.
This financial inflow masks the near-complete halt in operating revenue. The legacy animal feed business appears wound down, but the new pharmacy venture has yet to generate meaningful sales. Total expenses fell 65% year-on-year, reflecting this lack of commercial activity more than operational efficiency.
A balance sheet awaiting deployment
The company's financial position is now defined by this cash pile, with a current ratio of 77 and zero debt. However, cash flow from operations was negative ₹0.94 crore for the half-year, per InvestyWise. The capital is earmarked for a strategic shift.
Prism Medico has proposed reallocating ₹23 crore from cancelled manufacturing capex to acquire a controlling stake in related-party Infuze Well Private Limited, notes Flash Finance. This investment, pending from a recent AGM, is intended to establish a manufacturing subsidiary, representing the pivot's next phase.
Key Points
- Prism Medico's Q2 FY27 net profit of ₹0.23 crore was entirely driven by a surge in other income linked to a ₹17.5 crore capital raise.
- Core operating revenue fell 64% year-on-year to ₹0.18 crore, indicating the legacy business is dormant and the new pharmacy venture is not yet operational.
- The company holds a large cash balance with plans to invest ₹23 crore in a related-party manufacturing entity, marking the next step in its business transformation.
Hexa Perspective
The quarter confirms Prism Medico is a company between identities. The reported profit is a mirage of fundraising, not operating performance. The valuation, with a P/E of 116 against an industry average of 58, prices in a successful transformation that has not begun.
Investors are effectively funding a restart. The coming quarters will be judged solely on the deployment of the ₹23 crore investment and the subsequent generation of genuine pharmaceutical revenue. Until then, the financials reflect a corporate shell with a war chest, not a going concern.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
